These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24713880)

  • 1. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients.
    Brouwer ES; Napravnik S; Eron JJ; Stalzer B; Floris-Moore M; Simpson RJ; Stürmer T
    Epidemiology; 2014 May; 25(3):406-17. PubMed ID: 24713880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
    Obel N; Farkas DK; Kronborg G; Larsen CS; Pedersen G; Riis A; Pedersen C; Gerstoft J; Sørensen HT
    HIV Med; 2010 Feb; 11(2):130-6. PubMed ID: 19682101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.
    Ribaudo HJ; Benson CA; Zheng Y; Koletar SL; Collier AC; Lok JJ; Smurzynski M; Bosch RJ; Bastow B; Schouten JT;
    Clin Infect Dis; 2011 Apr; 52(7):929-40. PubMed ID: 21427402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
    Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D;
    Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
    Bedimo RJ; Westfall AO; Drechsler H; Vidiella G; Tebas P
    Clin Infect Dis; 2011 Jul; 53(1):84-91. PubMed ID: 21653308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
    Dorjee K; Desai M; Choden T; Baxi SM; Hubbard AE; Reingold AL
    AIDS Res Ther; 2021 Sep; 18(1):57. PubMed ID: 34488812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.
    Worm SW; Sabin C; Weber R; Reiss P; El-Sadr W; Dabis F; De Wit S; Law M; Monforte AD; Friis-Møller N; Kirk O; Fontas E; Weller I; Phillips A; Lundgren J
    J Infect Dis; 2010 Feb; 201(3):318-30. PubMed ID: 20039804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy.
    ;
    Clin Infect Dis; 2010 May; 50(9):1275-85. PubMed ID: 20353366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
    LaFleur J; Bress AP; Rosenblatt L; Crook J; Sax PE; Myers J; Ritchings C
    AIDS; 2017 Sep; 31(15):2095-2106. PubMed ID: 28692532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
    Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
    Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
    Tan DH; Chan K; Raboud J; Cooper C; Montaner JS; Walmsley S; Hogg RS; Klein MB; Machouf N; Rourke SB; Tsoukas C; Loutfy MR;
    J Acquir Immune Defic Syndr; 2011 Sep; 58(1):38-46. PubMed ID: 21709570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of antiretroviral therapy: implications of recent findings.
    Saag MS
    Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
    Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
    Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality in Children with Human Immunodeficiency Virus Initiating Treatment: A Six-Cohort Study in Latin America.
    Luque MT; Jenkins CA; Shepherd BE; Padgett D; Rouzier V; Succi RCM; Machado DM; McGowan CC; Vermund SH; Pinto JA
    J Pediatr; 2017 Mar; 182():245-252.e1. PubMed ID: 28081884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
    ; Cain LE; Phillips A; Olson A; Sabin C; Jose S; Justice A; Tate J; Logan R; Robins JM; Sterne JA; van Sighem A; Reiss P; Young J; Fehr J; Touloumi G; Paparizos V; Esteve A; Casabona J; Monge S; Moreno S; Seng R; Meyer L; Pérez-Hoyos S; Muga R; Dabis F; Vandenhende MA; Abgrall S; Costagliola D; Hernán MA
    Clin Infect Dis; 2015 Apr; 60(8):1262-8. PubMed ID: 25567330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.
    Smith KY; Tierney C; Mollan K; Venuto CS; Budhathoki C; Ma Q; Morse GD; Sax P; Katzenstein D; Godfrey C; Fischl M; Daar ES; Collier AC;
    Clin Infect Dis; 2014 Feb; 58(4):555-63. PubMed ID: 24253247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults.
    Tripathi A; Liese AD; Winniford MD; Jerrell JM; Albrecht H; Rizvi AA; Zhang J; Duffus WA
    Clin Cardiol; 2014 Sep; 37(9):517-22. PubMed ID: 25223811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.